ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Atomwise, a specialist in applying artificial intelligence (AI) to small-molecule drug discovery, will collaborate with South Korea’s Bridge Biotherapeutics on up to 13 molecules in multiple therapeutic areas. Atomwise will use its structure-based AI technology to initiate programs for Pellino E3 ubiquitin ligases and other targets nominated by Bridge. Atomwise will receive unspecified up-front payments, as well as milestone and royalty payments that could top $1 billion.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter